Roivant Sciences LTD. 8-K Filing
Ticker: ROIV · Form: 8-K · Filed: Nov 10, 2025 · CIK: 1635088
Sentiment: neutral
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-11-10 07:21:35
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20058314_8k.htm (8-K) — 27KB
- ef20058314_ex99-1.htm (EX-99.1) — 282KB
- 0001140361-25-041269.txt ( ) — 453KB
- roiv-20251110.xsd (EX-101.SCH) — 4KB
- roiv-20251110_lab.xml (EX-101.LAB) — 21KB
- roiv-20251110_pre.xml (EX-101.PRE) — 16KB
- ef20058314_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On November 10, 2025, Roivant Sciences Ltd. (the "Company") issued a press release announcing its financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information set forth under this "Item 2.02. Results of Operations and Financial Condition" (including the exhibit thereto) shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description of Exhibit 99.1 Roivant Sciences Ltd. Press Release, dated November 10, 2025. 104 Cover Page Interactive Data File (embedded with Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ROIVANT SCIENCES LTD. By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory Dated: November 10, 2025